Imugene Ltd (ASX: IMU) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Imugene Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $282.66 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 7.57 billion
Earnings per share -0.021
Dividend per share N/A
Year To Date Return -65.45%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Imugene Ltd (ASX: IMU)
    Latest News

    A woman with strawberry blonde hair has a huge smile on her face and fist pumps the air having seen good news on her phone.
    Share Gainers

    Why Graincorp, Imugene, iSelect, and Mayne Pharma shares are racing higher

    These ASX shares are on form on Wednesday...

    Read more »

    A man in a wheelchair stretches both arms into the air in success.
    Healthcare Shares

    Imugene share price lifts 11% on clinical trial update

    Imugene shares are flying higher today.

    Read more »

    Businessman cheering at desk with arms in the air
    Share Market News

    Here are the top 10 ASX 200 shares today

    These ten ASX 200 shares outperformed all others on Monday.

    Read more »

    A beautiful woman holds up one finger with one hand and has her hand on her waist with the other as she smiles widely as though she is very pleased about something.
    Share Gainers

    Why Appen, Imugene, OZ Minerals, and Paradigm shares are charging higher

    These ASX shares are starting the week strongly...

    Read more »

    Top ten gold trophy.
    Share Market News

    Here are the top 10 ASX 200 shares today

    These ASX 200 shares outperformed all others on Thursday.

    Read more »

    A woman stretches her arms into the sky as she rises above the crowd.
    Healthcare Shares

    Up 22% in a month, can the Imugene share price extend its rally?

    Imugene extends its gains today.

    Read more »

    A young woman wearing a blue blouse with white polkadots holds her phone up with an intrigued and happy look on her face as she reads some news.
    Share Market News

    Here are the top 10 ASX 200 shares today

    These 10 ASX 200 shares bested the rest on Tuesday.

    Read more »

    a doctor with stethoscope around neck sits as a computer with head in hand, looking despondent.
    Healthcare Shares

    Why is the Imugene share price sinking 13% this week?

    The Imugene share price is falling this week after a recent surge in value.

    Read more »

    A man slumps crankily over his morning coffee as it pours with rain outside.
    Share Fallers

    Why Appen, EML, Imugene, and Nanosonics shares are sinking

    These ASX shares are not having a good start to the week...

    Read more »

    Woman looking at a phone with stock market bars in the background.
    Share Market News

    ASX 200 midday update: ANZ's capital raising, Link jumps, Zip's Q4 update

    The ASX 200 is losing steam on Thursday...

    Read more »

    A man in a wheelchair stretches both arms into the air in success.
    Healthcare Shares

    The Imugene share price has rocketed 77% in a month. What's going on?

    The stock has made a notable comeback after a disappointing few months' trade.

    Read more »

    Scientists in a laboratory look at a computer screen with anticipation on their faces representing a potential change in the performance of ASX biotech shares in FY23
    Healthcare Shares

    What's the outlook for ASX biotech shares in FY23?

    ASX biotech shares could be changing course in FY23.

    Read more »

    Frequently Asked Questions

    Imugene does not pay dividends at this stage. 

    Imugene Ltd (ASX: IMU) listed on the ASX on 24 November 1993.

    IMU ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Imugene Ltd

    Imugene Ltd (ASX: IMU) is a biotechnology company working in cancer immunotherapy.

    The company specialises in clinical-stage immuno-oncology therapies. Its product pipeline includes Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard-care drugs and immunotherapies.

    The company's lead product is HER-Vaxx, a proprietary cancer vaccine for the treatment of gastric and breast cancer, where the cancer is HER-2 positive. The vaccine has demonstrated it stimulates a polyclonal antibody response to HER2/neu. 

    Imugene's various immunotherapy products are involved in ongoing clinical trials involving cancer specialists and researchers worldwide.

    IMU Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    20 Dec 2024 $0.04 $0.00 0.00% 13,295,359 $0.04 $0.04 $0.04
    19 Dec 2024 $0.04 $0.00 0.00% 14,581,638 $0.04 $0.04 $0.04
    18 Dec 2024 $0.04 $0.00 0.00% 8,346,749 $0.04 $0.04 $0.04
    17 Dec 2024 $0.04 $0.00 0.00% 6,179,996 $0.04 $0.04 $0.04
    16 Dec 2024 $0.04 $0.00 0.00% 13,301,017 $0.04 $0.04 $0.04
    13 Dec 2024 $0.04 $0.00 0.00% 7,071,023 $0.04 $0.04 $0.04
    12 Dec 2024 $0.04 $0.00 0.00% 14,482,883 $0.04 $0.04 $0.04
    11 Dec 2024 $0.04 $0.00 0.00% 20,312,321 $0.04 $0.04 $0.04
    10 Dec 2024 $0.04 $0.00 0.00% 5,432,216 $0.04 $0.04 $0.04
    09 Dec 2024 $0.04 $0.00 0.00% 9,881,013 $0.04 $0.04 $0.04
    06 Dec 2024 $0.04 $0.00 0.00% 18,460,644 $0.04 $0.04 $0.04
    05 Dec 2024 $0.04 $0.00 0.00% 27,652,698 $0.04 $0.04 $0.04
    04 Dec 2024 $0.04 $0.00 0.00% 40,813,474 $0.04 $0.04 $0.04
    03 Dec 2024 $0.04 $0.00 0.00% 9,729,505 $0.04 $0.04 $0.04
    02 Dec 2024 $0.04 $0.00 0.00% 10,114,522 $0.04 $0.04 $0.04
    29 Nov 2024 $0.04 $0.00 0.00% 3,498,605 $0.04 $0.04 $0.04
    28 Nov 2024 $0.04 $0.00 0.00% 11,950,068 $0.04 $0.04 $0.04
    27 Nov 2024 $0.04 $0.00 0.00% 15,641,203 $0.04 $0.04 $0.04
    26 Nov 2024 $0.04 $0.00 0.00% 7,251,618 $0.04 $0.04 $0.04
    25 Nov 2024 $0.04 $0.00 0.00% 11,101,427 $0.04 $0.04 $0.04
    22 Nov 2024 $0.04 $0.00 0.00% 31,276,637 $0.04 $0.04 $0.04

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    01 Jul 2024 Leslie (Mi Ok) Chong Exercise 5,793,750 $318,656
    Conversion of securities. 17,381,250 RIGHTS
    01 Jul 2024 Jens Eckstein Exercise 250,000 $13,750
    Conversion of securities. 750,000 RSU
    01 Jul 2024 Leslie (Mi Ok) Chong Transfer 1,500,000 $82,500
    As advised by the company. Transfer from direct to indirect holding
    01 Jul 2024 Leslie (Mi Ok) Chong Buy 5,793,750 $318,656
    Conversion of securities.
    01 Jul 2024 Jakob Dupont Exercise 250,000 $13,750
    Conversion of securities. 750,000 - Restricted Stock Units
    01 Jul 2024 Jakob Dupont Issued 250,000 $13,750
    Conversion of securities.
    01 Jul 2024 Kim Drapkin Exercise 250,000 $13,750
    Conversion of securities. 750,000 - Restricted Stock Units
    01 Jul 2024 Leslie (Mi Ok) Chong Transfer 1,500,000 $82,500
    As advised by the company. Transfer from direct to indirect holding
    01 Jul 2024 Kim Drapkin Issued 250,000 $13,750
    Conversion of securities. As per announcement on 08-07-2024
    01 Jul 2024 Lesley Russell Exercise 250,000 $13,750
    Conversion of securities. 750,000 - Restricted Stock Units
    01 Jul 2024 Paul Hopper Exercise 975,375 $53,645
    Conversion of securities. 2,926,125 PERFORMANCE RIGHTS AWARD
    01 Jul 2024 Jens Eckstein Issued 250,000 $13,750
    Conversion of securities.
    01 Jul 2024 Lesley Russell Issued 250,000 $13,750
    Conversion of securities.
    01 Jul 2024 Paul Hopper Issued 975,375 $53,645
    Conversion of securities.
    19 Apr 2024 Paul Hopper Sell 5,242,277 $381,113
    On-market trade.
    18 Apr 2024 Paul Hopper Sell 4,500,000 $363,600
    On-market trade.
    17 Apr 2024 Paul Hopper Sell 4,380,952 $365,285
    On-market trade.
    01 Feb 2024 Paul Hopper Issued 110,790,024 $1,717,245
    Issue of securities. Subject to release from escrow, as per announcement on 01-02-2024
    01 Feb 2024 Paul Hopper Issued 1,381,422 $21,412
    Issue of securities. Subject to release from escrow, as per announecment on 01-02-2024
    01 Feb 2024 Paul Hopper Transfer 10,000,000 $1,000,000
    As advised by the company. Transfer of shares for nil
    consideration.
    12 Jan 2024 Paul Hopper Issued 3,901,500 $468,180
    Issue of securities. 3,901,500 - Performance Rights
    12 Jan 2024 Jakob Dupont Issued 1,000,000 $120,000
    Issue of securities. 1,000,000 - RSUs
    12 Jan 2024 Jens Eckstein Issued 1,000,000 $120,000
    Issue of securities. 1,000,000 - RSUs
    12 Jan 2024 Kim Drapkin Issued 1,000,000 $120,000
    Issue of securities. 1,000,000 - RSUs
    12 Jan 2024 Leslie (Mi Ok) Chong Issued 23,175,000 $2,781,000
    Issue of securities. 23,175,000 - Performance Rights
    12 Jan 2024 Lesley Russell Issued 1,000,000 $120,000
    Issue of securities. 1,000,000 - RSUs

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Ms Leslie (Mi Ok) Chong Chief Executive OfficerManaging Director Nov 2016
    Ms Chong joined the Group from the leading oncology clinical development company, Genentech (a member of the Roche family), where she was a Senior Clinical Program Lead at the head office in San Francisco. She has over 25 years of experience in leading clinical and department development in oncology. In November 2016, Former directorships in last three years - Cure Brain Cancer Foundation (non-profit organisation), until 11 April 2023.
    Mr Paul Alex Hopper Executive ChairmanExecutive Director Dec 2013
    Mr Hopper has over 20 years of experience in the management and funding of biotechnology and healthcare public companies as chairman, chief executive officer and director in Australia and the United States. Mr Hopper's sector experience has covered therapeutic areas with emphasis on immunotherapy. He also has capital markets experience in equity and debt raisings in Australia, Asia, Europe, and the United States. Former directorships in last three years include Scopus BioPharma Inc (NASDAQ: SCPS), until 18 May 2022.
    Dr Lesley Russell Non-Executive Director Apr 2019
    Dr Russell is a haematologist/oncologist and has over 25 years of experience and leadership in the international pharmaceutical field as a Chief Medical Officer. She has undertaken clinical development in a number of therapeutic areas including haematology/oncology and has had new drug approvals with FDA and European Medicines Agency. Dr Russell has experience as a director of NASDAQ listed pharmaceutical companies. She is a member of the Royal College of Physicians UK. Other current directorships - Enanta Pharmaceuticals (NASDAQ: ENTA), since 22 November 2016. Dr Russell is member of Risk Committee.
    Dr Jakob Dupont Non-Executive Director Sep 2022
    Dr Dupont is an industry and drug development expert with more than 20 years of experience specialising in oncology and other therapeutic areas. Dr Dupont is currently the Executive Venture Partner at Sofinnova Investments. Dr Dupont's experience includes NASDAQ listed Atara Biotherapeutics (NASDAQ: ATRA), where he oversaw all research and development, including three clinical stage programs spanning Phase 1 through to Phase 3, and preclinical programs. Other current directorships include Pyxis Oncology (NASDAQ: PYXS); Avenzo Therapeutics and Flagship Pioneering (Scientific Advisory Board). Former directorships in last three years - Apexigen (NASDAQ: APGN) until August 2023. Dr Dupont is member of the Risk Committee.
    Ms Kim Drapkin Non-Executive Director Jun 2023
    Ms Drapkin has over 25 years of experience working with private and publicly traded biotechnology and pharmaceutical companies, including building and leading finance functions, raising capital, and leading strategic financial planning. In addition to Imugene, Ms Drapkin currently serves on the board of directors at Acumen Pharmaceuticals (NASDAQ: ABOS) where she chairs the audit committee and is a member of the compensation committee and LENZ Therapeutics (NASDAQ: LENZ) where she is a member of the compensation and governance committees. Recently, Ms Drapkin was CEO and a board member at Graphite Bio where she led the strategic alternatives process culminating in a reverse merger with LENZ Therapeutics. Prior to that, Ms Drapkin was CFO at Jounce Therapeutics since its inception, playing a role in building Jounce's financial infrastructure. Prior to joining Jounce, Ms Drapkin owned a financial consulting firm where she served as the interim chief financial officer for early stage biotechnology companies. Previously, Ms Drapkin was chief financial officer at EPIX Pharmaceuticals. Prior to EPIX, Ms Drapkin spent ten years in roles of increasing responsibility within the finance organisation at Millennium Pharmaceuticals. Ms Drapkin began her career in the technology and life sciences practice at PriceWaterhouseCoopers LLP. Other current directorships are held with Acumen Pharmaceuticals (NASDAQ: ABOS); LENZ Therapuetics (NASDAQ: LENZ). Former directorships in last three years - Yumanity Therapeutics (NASDAQ: YMTX); Proteostasis Therapeutics (NASDAQ: PTI). She is chair of risk committee.
    Mr Michael (Mike) Tonroe Chief Financial OfficerCompany Secretary Mar 2023
    -
    Monil Shah Chief Business Officer
    -
    Mike Tonroe Chief Financial Officer
    -
    Michael (Mike) Tonroe Chief Financial OfficerCompany Secretary
    -
    Paul Woodard Chief Medical Officer
    -
    Bradley Glover Chief Operating Officer
    -
    Nicholas Ede Chief Technology Officer
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Paul Hopper 409,071,906 5.57%
    JP Morgan 283,996,697 3.86%
    Citicorp Nominees Pty Limited 266,813,810 3.63%
    Mann Family 265,582,609 3.61%
    HSBC Custody Nominees (Australia) Limited i 213,532,203 2.91%
    Dr Nicolas Smith 118,000,000 1.61%
    Netwealth Investments Limited <Wrap Ser Vices A/C> 85,488,611 1.16%
    Mi Ok Chong 78,416,666 1.07%
    BNP Paribas Noms Pty Ltd 70,407,583 0.96%
    National Nominees Pty Ltd 60,113,645 0.82%
    UBS Nominees Pty Ltd 50,328,041 0.68%
    BNP Paribas Noms Pty Ltd <Ib Au Noms Retail Client> 48,979,324 0.67%
    HSBC Custody Nominees (Australia) Limited ii 29,079,510 0.40%
    Mr Phillip Wood 25,480,000 0.35%
    Sve Capital Pty Ltd <Strategic Vision Unit A/C> 23,000,000 0.31%
    Dr Yuman Fong 22,379,032 0.30%
    Dr Jen Eckstein 20,738,095 0.28%
    Dr Lesley Russell 20,238,095 0.28%
    Citicorp Nominees Pty Limited <Colonial First State Inv A/C> 20,230,709 0.28%
    Mr Scott Spencer Pappin & Mrs Tracey Lee Pappin <Pappin Super Fund A/C> 20,000,000 0.27%
    Jem Investment Fund Holdings Pty Ltd <Jem Invest Fund Family A/C> 20,000,000 0.27%

    Profile

    since

    Note